Democrats move to investigate Trump drug pricing deals

Incoming Democratic committee chairs are preparing to investigate Most-Favored-Nation (MFN) drug pricing agreements between drugmakers and the Trump administration. The move signals a shift in oversight priorities and could pressure pharmaceutical companies and the administration. The scope and timing of the investigation remain unclear.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works